Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

7Total
P 1 (6)
P 2 (1)

Trial Status

Recruiting4
Enrolling By Invitation1
Withdrawn1
Active Not Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT05843253Phase 2Recruiting

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

NCT06342908Phase 1Active Not RecruitingPrimary

A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma

NCT06630260Phase 1Recruiting

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

NCT07223034Phase 1Recruiting

A Study of 177Lu-PSMA-617 in People With Gliomas

NCT06896110Phase 1Enrolling By Invitation

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

NCT06632236Phase 1Recruiting

5G-EMERALD: Amivantamab in Malignant Brain Tumours

NCT05457959Phase 1WithdrawnPrimary

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Showing all 7 trials

Research Network

Activity Timeline